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Abstract
Background: Androgens bind to the androgen receptor (AR) in prostate cells and are essential survival factors for 
healthy prostate epithelium. Most untreated prostate cancers retain some dependence upon the AR and respond, at 
least transiently, to androgen ablation therapy. However, the relationship between endogenous androgen levels and 
cancer etiology is unclear. High levels of androgens have traditionally been viewed as driving abnormal proliferation 
leading to cancer, but it has also been suggested that low levels of androgen could induce selective pressure for 
abnormal cells. We formulate a mathematical model of androgen regulated prostate growth to study the effects of 
abnormal androgen levels on selection for pre-malignant phenotypes in early prostate cancer development.
Results: We find that cell turnover rate increases with decreasing androgen levels, which may increase the rate of 
mutation and malignant evolution. We model the evolution of a heterogeneous prostate cell population using a 
continuous state-transition model. Using this model we study selection for AR expression under different androgen 
levels and find that low androgen environments, caused either by low serum testosterone or by reduced 5α-reductase 
activity, select more strongly for elevated AR expression than do normal environments. High androgen actually slightly 
reduces selective pressure for AR upregulation. Moreover, our results suggest that an aberrant androgen environment 
may delay progression to a malignant phenotype, but result in a more dangerous cancer should one arise.
Conclusions: The model represents a useful initial framework for understanding the role of androgens in prostate 
cancer etiology, and it suggests that low androgen levels can increase selection for phenotypes resistant to hormonal 
therapy that may also be more aggressive. Moreover, clinical treatment with 5α-reductase inhibitors such as finasteride 
may increase the incidence of therapy resistant cancers.
Reviewers: This article was reviewed by Ariosto S. Silva (nominated by Marek Kimmel) and Marek Kimmel.
Background
By the time Theodosius Dobzhansky famously claimed 
that "nothing in biology makes sense except in the light of 
evolution" [1], cancer was already becoming an excellent 
illustration of his point. In fact, two decades before 
Dobzhansky's claim appeared in print, Law [2] demon-
strated that, at least in a mouse model, leukemia develops 
resistance to folic acid antagonists by natural selection, 
not accommodation. By the mid 1970s the significance of 
evolution in tumor progression, pathogenesis, and treat-
ment resistance was maturing [3], with interest in evolu-
tionary oncology exploding the in the 1990s [4-10]. Now, 
cancer is increasingly understood to be an evolutionary 
phenomenon, although the conditions for evolution by 
natural selection have been demonstrated unequivocally 
in only one neoplasm--Barrett's esophagus [11].
Until recently it was an open question whether insights 
generated by an evolutionary perspective could be trans-
lated to the oncology clinic. However, in the last 10 years 
a wide variety of potential applications has arisen. Evolu-
tionary models of neoplasia led Gatenby, Gawlinsky and 
colleagues [12-14] to hypothesize that tumor-associated 
tissue acidosis may be caused by natural selection favor-
ing glycolytic cells in developing carcinomas. Selection 
for this property, in turn, facilitates invasion of surround-
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leagues [15,16] suggest a novel treatment approach--
altering the environment to favor benign tumoral and 
peritumoral cells, instead of the traditional attacks on 
malignant cells, can be an effective adjuvant, or perhaps 
primary, anti-cancer treatment. Maley and colleagues 
[17] have also shown that ecological measures of clonal 
diversity predict progression to esophageal adenocarci-
noma in Barrett's esophagus in a pattern that is in turn 
predicted by evolutionary oncology theory [6,10,17]. 
More detailed phylogenetic analysis of tumor cell lineages 
may shed light on tumor progression in individual 
patients [9]. Mathematical models of tumor evolutionary 
ecology suggest that if selection is dominated by competi-
tion among diverse cell lineages, one lineage may adopt a 
"cheater" strategy leading to a "hypertumor"--the cheater 
clone growing as a tumor on its parent tumor [8,18,19]. 
Coevolution among lineages may also produce coopera-
tive cell types that act in some ways like tissues. A similar 
pattern may arise if malignant cell lineages diversify to 
exploit different resources or changing environments 
[10,18].
Despite these contributions, application of an evolution-
ary perspective to clinical oncology still suffers from a 
lack of maturity. In particular, the theory of tumor ecol-
ogy--the theater in which evolution occurs--is critical, yet 
not well characterized for most tumor types [8-10]. One 
reason for this hole in our theory is that tumor ecologies 
feature unique elements not observed in traditional eco-
logical systems. For example, in prostate cancer, ecologi-
cal elements like the hormonal environment, redox state, 
and tissue inflammation have no obvious counterparts in 
an ecosystem as traditionally defined, but may play key 
roles in cancer pathology. Androgens, for example, medi-
ate proliferation, apoptosis, oxidative stress, and perhaps 
inflammation in the prostate, and are therefore likely pri-
mary mediators of selective pressure in the evolution of 
prostate cancer.
This particular neoplasm is interesting for a number of 
reasons in addition to its unique ecological features. It 
accounts for 25% of new cancer diagnoses and 10% of 
cancer deaths in American men [20]. Most men develop 
prostate enlargement at some point in life, and autopsies 
show that, worldwide, 90% of men in their 10th decade of 
life have developed at least preclinical prostate cancer 
[21]. The aggressiveness of diagnosed cancers varies 
widely, but over 90% of prostate cancer cases are diag-
nosed at local or regional stages for which survival 
approaches 100% [20]. The natural history of this neo-
plasm is widely believed to span decades in most men 
[21]. This long preclinical phase suggests a typically slow 
evolutionary progression toward the malignant pheno-
type; how ecological factors drive this selective process is 
not known.
Androgens, the male sex hormones, have long been cen-
tral to the study and treatment of prostate cancer. Andro-
gens are essential survival factors for prostate secretory 
epithelial cells and act by binding with the androgen 
receptor (AR). Testosterone, the primary androgen in the 
serum, is converted to 5α-dihydrotestosterone (DHT) by 
the enzyme 5α-reductase in the prostate [22]. Testoster-
one and DHT both bind to AR, but DHT is more active, 
displaying greater binding affinity and stabilization of the 
AR complex [23]. Upon binding, androgen:AR complexes 
are phosphorylated, dimerize, and translocate to the 
nucleus, where they bind to the promoter regions of tar-
get genes [24] to modulate the transcriptional activity of 
at least several hundred target genes.
The importance of androgens is readily demonstrated by 
rat castration models. Following castration, over 70% of 
androgen sensitive cells undergo apoptosis [22], and the 
prostate epithelial mass decreases dramatically to only 7% 
of its original mass at 21 days [25]. Exogenous androgens 
induce prostate regrowth [23,26], but high levels of 
androgen alone do not generally induce the prostate to 
grow beyond its normal size; androgen induced prolifera-
tion is apparently regulated by the normal prostate cell 
count, although the mechanism for this is unclear [26].
Androgens are essential for normal prostate develop-
ment, and deficiencies in 5α-reductase can severely 
impair prostate development [22]. Not only are andro-
gens essential for prostate development, but changes in 
the androgen environment appear to mediate age-associ-
ated tissue remodeling. Serum testosterone declines with 
age in both the rat and man, leading to heterogeneous tis-
sue remodeling in both animals. In the brown Norway rat 
(Rattus norvegicus), spontaneous hyperplasia associated 
with increased AR expression in the dorsal and lateral 
lobes is observed, while the ventral lobe may atrophy with 
age [27]. Men often experience benign prostatic hyper-
plasia (BPH), a disorder generally considered unrelated to 
prostate cancer, that is characterized by extensive hyper-
plasia of the stroma in the prostate transition zone 
[27,28]. Such changes in the microenvironment may alter 
the prostate cell turnover, count, genetic instability, and 
stress, and thus affect the selective environment that 
aging epithelial cells are exposed to. Most clinical pros-
tate cancers are AR-dependent, and this observation has 
motivated androgen ablation therapy. Such therapy con-
sists of chemical or surgical castration, which reduces 
serum testosterone by up to 95%, but reduces intrapros-
tatic DHT levels by only 50% [22]. More complete andro-
gen blockade can be achieved by supplementing 
castration with anti-androgens such as flutamide, niluta-
mide, and bicalutamide, and such therapy is referred to as 
maximal androgen blockade (MAB) [24]. However, the 
benefit to MAB over castration is uncertain, and a large 
meta-analysis suggested that any additional benefit to 
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androgen ablation, and often experience dramatic cancer 
regression. However, most cancers progress to a hormone 
refractory (HR) state even with near total androgen abla-
tion, and while time to progression can vary greatly [24], 
recurrence occurs on average between 12 and 18 months 
following treatment [22]. Most cancers are more aggres-
sive following HR recurrence, there are no effective treat-
ments for such cancers, and average survival following 
progression does not exceed 15 months [24]. These can-
cers are often referred to as androgen independent, but 
most retain at least some dependence on the AR for sur-
vival.
Several major mechanisms for hormone refractory recur-
rence have been identified. Modification of AR signaling, 
in one form or another, is the dominant theme in HR can-
cer progression. In a minority of cancers, DNA-based 
alterations to the AR allow it to bind to non-canonical 
ligands such as estrogen and cortisone, and in some 
cases, clinical AR antagonists such as flutamide [30]. AR 
gene amplification occurs in perhaps 30% of recurring 
HR tumors [22]. However, such genetic alterations do not 
occur in the majority of HR cancers. Upregulation of 5α-
reductase has also been identified as promoting recur-
rence [31], and overexpression of AR coactivators is asso-
ciated with progression [22].
Several androgen independent pathways also exist. 
Upregulation of bcl-2, bcl-x, and mcl-1 protect against 
apoptosis independently of androgens, and expression of 
such proteins has been found to increase with cancer pro-
gression [32]. Many growth factors can activate signal 
transduction cascades that phosphorylate and activate 
the AR in a ligand-independent manner [22,30]. Tyrosine 
kinase receptor activation can induce survival and prolif-
eration independently of the AR. The epidermal growth 
factor (EGF) family of proteins, and in particular HER2, 
promote androgen independent cancer growth [22], as 
can fibroblast growth factors [33] and insulin-like growth 
factor-1 (IGF-1) [22].
Upregulation of the AR protein is perhaps the single most 
important pathway by which cancers achieve androgen 
"independence". Chen et al. [30] found that in 7 prostate 
cancer xenograft models, increased androgen receptor 
expression was the only change consistently associated 
with HR cancer progression. Increased AR levels pro-
moted growth in a ligand-dependent manner. Higher AR 
also altered cofactor recruitment to be biased towards 
coactivators, and it was even shown that high AR expres-
sion converted AR antagonists to weak agonists. Rapid 
HR cancer recurrence in a xenograft model by Rocchi et 
al. was always associated with increased AR expression 
[31].
Castration and androgen blockade in aggressive cancer is 
not the only setting in which androgens are manipulated 
clinically. 5α-reductase inhibitors are commonly used to 
treat both benign prostatic hyperplasia and alopecia (hair 
loss). Finasteride (Propecia, Proscar), the most common 
5α-reductase inhibitor, is commonly used to treat BPH, 
and can reduce prostate volume and improve symptoms 
[28]. However, BPH in man is characterized by stromal, 
not epithelial, overgrowth [34] and is characterized by an 
elevated stroma:epithelium ratio [33,34]. Finasteride 
treatment targets the epithelium, with little if any effect 
seen on the stroma [34], and it dramatically increases the 
prostate stroma:epithelium ratio [28].
Because of their role in protecting against apoptosis and 
promoting proliferation and the (transient) efficacy of 
androgen ablation therapy, it has long been thought that 
high levels of androgens play a causal role in prostate can-
cer development. The fact that eunuchs and men with 
genetic deficiencies in 5α-reductase do not typically 
experience prostate cancer, along with the fact that 
androgen deprivation causes cancer regression have long 
been cited in support of this notion. But, as Raynaud 
recently pointed out [35], such scenarios have little if any-
thing to do with cancer development under the normal 
physiologic androgen range. In support of the high 
androgen hypothesis, in several animal models androgens 
were capable of inducing cancer, and some clinical stud-
ies have suggested a link between high testosterone and 
cancer incidence [26,35].
In 1999, Prehn [26] proposed an alternate hypothesis: 
that low levels of androgen creates selective pressure for 
prostate cells that are less dependent upon androgen for 
growth. Declining levels of androgen could result in 
hyperplastic foci resistant to atrophy and susceptible to 
further neoplastic transformation. In indirect support of 
this hypothesis, a number of clinical studies have failed to 
support the notion that high androgen levels increase the 
risk of prostate cancer [35-38], and some data suggests 
that low serum testosterone is associated with aggressive, 
therapy-resistant tumors. In a prospective study includ-
ing 17,049 men, high serum testosterone did not increase 
risk of prostate cancer and lowered the risk of aggressive 
tumors [39], and Sofikerim et al. recently found a signifi-
cantly increased risk of cancer detection in men with low 
versus high serum testosterone [36]. Such data has led 
many authors to conclude that normal or high androgen 
promotes normal differentiation and function in epithe-
lial cells, protecting against rather than promoting car-
cinogenesis [35,39]. Such results do not necessarily 
indicate a causal link between low androgen levels and 
carcinogenesis, and other authors have suggested that 
low testosterone reflects the poorer health of those expe-
riencing aggressive cancers [40,41].
Although the role of androgens in predicting the inci-
dence of prostate cancer has not been definitively settled, 
a broad literature dating from at least 1981 has consis-
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apy in men with low pre-treatment serum testosterone 
[40,42-48]. Testicular atrophy is particularly strongly 
associated with aggressive cancers and a very poor 
response to therapy [49].
The effect of finasteride, which also modifies the intra-
prostatic androgen environment, on prostate cancer risk 
is unclear and controversial. The Prostate Cancer Preven-
tion Trial (PCPT) randomly assigned men to receive daily 
finasteride (5 mg) or placebo for 7 years. Prostate biopsy 
was performed either for elevated adjusted serum PSA or 
abnormal digital rectal exam (DRE) findings. Moreover, 
all consenting participants were given an end-of-study 
biopsy. Finasteride use reduced overall prostate cancer 
incidence by 24%, but increased the risk of high-grade 
cancer over 7 years: 37% of cancers were high-grade in 
the treatment group versus 22% in the placebo group 
[50]. This result has sparked much debate over whether 
the increased incidence of high-grade tumors was a 
pathological artifact. Finasteride significantly reduced the 
prostate size in those treated, and reduced prostate size 
can increase the probability of cancer detection in biopsy 
samples: a lower overall prostate volume increases the 
probability that tumor tissue will be present in a biopsy 
core. Therefore, a detection bias could explain the 
increased rate of high-grade cancer. Lucia et al. [51] have 
argued that detection bias and changes in prostate histol-
ogy induced by finasteride may account for the increased 
risk of high-grade tumors seen in the PCPT. However, a 
large study by Briganti et al. [52] where prostatectomy 
controlled for detection bias indicated that smaller pros-
tates tend to harbor intrinsically more aggressive cancers. 
Freedland et al. [53] also found the weight of resected 
prostate specimens to be inversely associated with dis-
ease grade and risk of progression. These findings suggest 
that the increased risk of high-grade cancer seen in the 
PCPT may not have been an artifact. A recent review of 
RCTs concluded that 5α-reductase treatment reduces 
overall cancer incidence but may increase the risk of 
high-grade cancer [54]. This issue is particularly relevant, 
as a recently published clinical guideline stated that 
healthy men may benefit from a discussion of the risks 
and benefits of taking finasteride for primary chemopre-
vention of prostate cancer [55]. In light of these contro-
versies, we focus upon understanding how different 
androgen environments promote carcinogenesis.
Several other investigators have used mathematical mod-
els to study androgens and prostate cancer. Jackson 
[56,57], and later Ideta et al. [58], used models to study 
selection for androgen independent strains following 
androgen ablation in aggressive prostate cancers. Potter 
et al. [59] also developed an exhaustive model of serum 
androgen dynamics and their effect on healthy prostate 
growth. Unlike Jackson, Ideta, and their colleagues, we 
focus not upon the evolution of prostate cancer in 
response to hormonal therapy, but rather upon the role 
androgens play in the evolutionary theater of early, pre-
clinical prostate cancer.
In particular, we explore the selection process for pre-
malignant phenotypes using a simple mathematical 
framework that considers prostate growth mediated by 
androgens at both the receptor kinetics level and tissue 
growth level; we also model multiple strains competing 
within a tissue. In this model, prostate growth is 
restricted by the homeostatic prostate size. That is, we 
assume that homeostatic mechanisms that prevent 
unbounded prostate growth are intact. Therefore, we 
consider only the earliest stage of molecular oncogenesis, 
where changes in gene expression influence proliferative 
or apoptotic activity, but before phenotypes allowing tis-
sue invasion or metastasis have arisen. We model the 
chemical kinetics of intracellular androgen conversion 
from testosterone to DHT and the binding of these 
ligands to the AR. This model is used to inform a tissue-
level model of the proliferation and death of prostate epi-
thelial cells. We characterize the basic dynamics of both 
the AR kinetics and the coupled kinetics-growth model. 
We determine how both prostate epithelial mass and cell 
turnover rates change under different hormone environ-
ments.
Finally, this model is applied to an evolving, heterogenous 
cell population in which cell strains vary in AR expres-
sion. We focus upon the evolution of AR expression 
because of its deep importance in hormone therapy resis-
tance and the fact that higher AR expression has been 
correlated with higher grade tumors [22,37]. We find that 
low serum testosterone strongly selects for greater AR 
expression. We also find that treatment with finasteride 
(i.e. 5α-reductase inhibition) similarly selects for 
increased AR expression. Together, these results suggest 
that low androgen environments select more strongly for 
hormone therapy resistant and possibly more aggressive 
cancer strains than do normal or elevated androgen envi-
ronments.
Methods
Mathematical Model
We develop a minimal model of proliferation and apopto-
sis in prostate epithelium mediated by androgens. We 
model this on two levels: the first is a chemical kinetics 
scheme of the intracellular activity of androgens and their 
binding the AR. The second level of the model correlates 
the intracellular concentration of DHT:AR and T:AR 
complexes with proliferative and apoptotic activity.
Potter et al. [59] developed a thorough model describing 
androgenic regulation of prostate growth in the rat, and 
we are indebted to their model as a guide.
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The intracellular chemical kinetics model is outlined as 
follows:
1. Free testosterone influx into the prostate is an 
empirical function of serum testosterone concentra-
tion, and this testosterone is uniformly distributed to 
the intracellular compartment of all prostate cells.
2. Free intracellular testosterone is converted to free 
DHT by the enzyme 5α-reductase. The intraprostatic 
5α-reductase level is assumed to be a constant.
3. Free testosterone and DHT both degrade according 
to first-order kinetics.
4. Free testosterone and DHT bind to AR to form 
T:AR and DHT:AR complexes according to mass 
action kinetics. These complexes do not degrade.
5. Intracellular free AR binds to testosterone and 
DHT according to mass action kinetics, degrades by 
first order kinetics, and is produced at a rate that 
depends upon the homeostatic AR concentration and 
current free AR concentration.
The following variables are considered:
1. TS(t) = Total serum testosterone concentration 
(nM),
2. R(t) = Free intracellular androgen receptor concen-
tration (nM),
3. T (t) = Free intracellular testosterone concentration 
(nM),
4. D(t) = Free intracellular DHT concentration (nM),
5. CT:R(t) = T:AR complex concentration (nM),
6. CD:R(t) = DHT:AR complex concentration (nM).
The basic mass action binding between T and DHT with 
AR and the conversion from T to DHT by 5α-reductase is 
illustrated schematically as
Translating this scheme into an ODE, and also taking into 
account T influx, AR production, and free T, DHT, and 
AR degradation yields the following chemical kinetics 
model:
The rate of AR production is given as λ, and AR, T, and 
DHT degrade at rates βR, βT, and βD, respectively. 5α-
reductase converts T to DHT by Michaelis-Menten 
enzyme kinetics, where α is the concentration of 5α-
reductase, kcat is the turnover number, i.e. the maximum 
rate at which T is converted to DHT by each unit of 
enzyme, and KM is the Michaelis constant. Parameters 
 are the mass action rate constants for T 
and DHT binding to AR.
We have also assumed that all prostate androgens are 
intracellular and uniformly distributed among the epithe-
lial cells. We ignore all the details of transport between 
serum, extracellular, and intracellular compartments, and 
instead have testosterone transported directly into the 
intracellular compartment. We leave U, the rate of test-
osterone influx into the intracellular prostate compart-
ment, an unspecified function of the serum testosterone 
level,
The exact form for this function is determined empiri-
cally in the section on parametrization. Serum testoster-
one (TS), while in reality a function of time, is always 
imposed in our model and does not vary according to a 
governing ODE. Significantly, we have not modeled 
dimerization of androgen:AR complexes or their nuclear 
localization and binding to gene promoter regions under 
the assumption that the concentrations of androgen:AR 
complexes can be taken as surrogates for such activities.
We assume that prostate cells maintain a constant con-
centration of total AR (the sum of bound and unbound 
AR). We define Rt as the homeostatic AR concentration, 
and at steady state we have:
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maintained at Rt by modification of the AR production 
rate, λ, as follows:
where  is the normal AR turnover rate. A more exten-
sive discussion of this assumption is included in the AR 
kinetics parametrization section.
We also pay special attention to the effect of 5α-reduc-
tase inhibition by finasteride. Finasteride is a competitive 
inhibitor of 5α-reductase, implying that it increases the 
effective KM. The rate of conversion from T to DHT by 
5α-reductase is modified to
Where
I is the concentration of the inhibitor and KI is its dissoci-
ation constant.
Prostate Growth Model
We now link intracellular androgen concentrations to the 
proliferation and apoptosis of prostate epithelial cells. 
While we generally refer to low or high androgen levels 
causing a behavior, it is really the concentrations of AR:T 
and AR:DHT complexes that mediate these androgen 
related activities. We introduce the variable Ct to repre-
sent the "effective" androgen:AR concentration. In [60], 
DHT was 2.4 times as potent as T in maintaining prostate 
weight and duct lumen mass, and these quantities varied 
linearly with the concentration of either androgen. 
Therefore, we take Ct to be a simple linear combination of 
CT:R and CD:R,
Thus, Ct has units of nM and represents the concentra-
tion of AR:T equivalents. This approach allows the previ-
ously developed androgen kinetics model (equations 1-6) 
to be coupled directly to a model of prostate growth 
mediated by androgens. We let P(t) represent the number 
of prostate epithelial cells. We assume that the change in 
P is governed by two distinct death and proliferation sig-
nals; the per-capita proliferation rate is M(Ct, S) and the 
per-capita death rate is N(Ct, S), implying the basic model 
framework:
where S represents oxidative stress. We now determine 
the formal forms for M(Ct, S) and N(Ct, S). Prostate epi-
thelial proliferation and death are regulated by androgens 
in several ways:
1. Androgens induce the prostate stroma to produce 
factors, mainly bFGF and FGF-7, that support epithe-
lial growth in a paracrine manner by supporting the 
prostate vasculature, inducing epithelial proliferation, 
protecting the epithelium from apoptosis, and regu-
lating AR protein levels.
2. Androgens may have a direct mitogenic effect upon 
epithelial cells through upregulation of proteins 
required for cell cycle progression.
3. Androgens directly protect against apoptosis by 
negatively regulating TGF-β and increasing bcl-2 lev-
els.
4. Androgens mediate oxidative stress and the pro-
duction of reactive oxygen species (ROS) within epi-
thelial cells which can induce proliferation, stasis, or 
death, depending upon the concentration.
In response to androgen withdrawal, rat prostate mass 
decreases dramatically through both apoptosis and atro-
phy. For modest androgen ablation, cellular atrophy and 
loss of prostatic fluid through loss of secretory function is 
primarily responsible for lost mass [60]. More extreme 
ablation, typically through castration, results in rapid and 
widespread epithelial cell apoptosis [22,25,61].
Androgens clearly protect against epithelial apoptosis. 
TGF-β expression by prostate epithelium is negatively 
regulated by androgen [61], and this factor appears to be 
necessary for apoptosis in response to low androgen [22]. 
bFGF produced by the stroma in response to androgens 
increases prostatic bcl-2 [22], an important anti-apopto-
sis protein that has also been implicated in late-stage 
prostate cancer progression [30]. Androgens also posi-
tively regulate the expression of a number of proteins that 
protect against apoptosis and downregulate others that 
induce apoptosis, such as TIMP3 [62].
It is generally accepted that androgens induce epithelial 
proliferation in vivo when the cell count is below normal, 
and androgen administration following castration 
induces rapid prostate regrowth in the rat [23,61]. How-
ever, proliferation is thought to be limited, at least to 
some degree, by the homeostatic size of the prostate 
[26,63]. It is unclear to what extent androgens are directly 
mitogenic for prostate epithelium, since much of the 
mitogenic effect is due to stroma-epithelium interactions 
λ β= − −R t TR DRR C C*( ), (8)
βR*
α ηk
T
K Tcat M +
, (9)
η = +1 I
K I
,
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dP
dt
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failed to demonstrate epithelial proliferation in response 
to androgen alone [64]. Several proteins required for cell 
cycle progression are positively regulated by androgens 
(cyclin D1, cdc2, PCNA), as are several that inhibit the 
cell cycle (geminin, GADD45γ) [62]. Androgens induce 
stromal production of bFGF and FGF-7, which have weak 
and strong mitogenic effects on the epithelium, respec-
tively [33]. Interestingly, bFGF also reduces levels of AR 
in prostate epithelium, and while bFGF independently 
induces epithelial proliferation, it can slow androgen 
induced growth [65]. bFGF and vascular endothelial 
growth factor (VEGF) both are produced by the stroma in 
response to androgens and play an essential role in sup-
porting the prostate vasculature [22].
Many studies focusing on the rat ventral prostate have 
suggested that high androgen levels alone can induce 
prostate epithelial cell hypertrophy but not hyperplasia 
[66]. Several studies by Banerjee et al. [27,67] on the 
brown Norway rat demonstrated that high androgen 
could induce hyperplasia in the lateral and dorsal prostate 
lobes, but not the ventral, and that this was related to 
increased AR expression in these lobes. Furthermore, 
aging was correlated with spontaneous hyperplasia in the 
dorsal and lateral lobes despite declining serum testoster-
one levels [27,66]. This hyperplasia was itself correlated 
with increased AR expression [27]. Saturation of the AR 
by its ligand therefore may be at least partially responsi-
ble for the failure of excess androgen to induce hyperpla-
sia under normal conditions. This notion is supported by 
our model parametrization, where we estimate the nor-
mal intracellular concentrations of AR and DHT to be 45 
nM and about 40-60 nM, respectively. An alteration in 
the testosterone:estrogen ratio in the aging rat was also 
suggested as having a possible causal connection to 
hyperplasia.
Thus, while normal prostate cell count is generally main-
tained, age-associated changes in the hormonal milieu 
and AR levels are likely able to induce hyperplasia and 
excessive androgen-induced proliferation. In our model, 
we assume that high levels of androgen directly induce 
proliferation while low levels cause apoptosis.
The prostate redox state is also influenced by androgens, 
and this may be deeply important in epithelial death, pro-
liferation, and carcinogenesis. The mitochondria are the 
major source of reactive oxygen species (ROS). A signifi-
cant amount of superoxide anion  is produced as a 
side-product of aerobic respiration, and  can gener-
ate a number powerful oxidants through further reac-
tions [68]. Ubiquitous ROS include , H2O2 and the 
hydroxyl radical (HO•) [69].
Androgen blockade induces the production of ROS and 
subsequent oxidative stress. Both finasteride and fluta-
mide (an anti-androgen) dramatically increased the 
expression of the pro-oxidant enzyme L-amino oxidase-1 
(LaO1), which generates H2O2, in the rat ventral prostate 
[70]. Tam et al. [69] showed that rat castration results in 
dramatic upregulation of ROS generating NADPH oxi-
dases (NOXs) and downregulation of ROS-detoxifying 
enzymes, including superoxides dismutase 2 (SOD2) and 
thioredoxin. Androgen re-administration restored anti-
oxidant defenses, but only partially reduced NOX expres-
sion. Several other antioxidant proteins were not affected 
by castration, but were upregulated upon androgen re-
administration. Pang et al. [71] also found that the 
expression of a number of antioxidant genes was down-
regulated following rat castration and suggested that this 
is a possible mechanism for castration-induced apopto-
sis.
Vascular regression caused by androgen withdrawal pre-
cedes epithelial apoptosis, causing hypoxia and a dra-
matic increase in hypoxia inducible factor-1α (HIF-1α) 
[72]. Hypoxia impairs aerobic respiration, increasing 
mitochondrial ROS production. Such mitochondrial ROS 
is required for stabilization of HIF-1α [73]. Thus, in addi-
tion to direct effects on redox related enzymes, a low 
androgen environment also increases ROS levels by 
inducing a hypoxic environment.
Androgen administration has also been shown to induce 
oxidative stress. Tam et al. [74] found that administration 
of testosterone with 17β-estradiol increased several 
NOXs, nitric oxide synthases (NOSs), and cyclooxygen-
ase-2 (COX-2), resulting in oxidative and nitrosative 
stress in the lateral lobe of the Noble rat. Ripple et al. [75] 
found that physiologic levels of DHT induced ROS in the 
LNCaP carcinoma cell line, and ROS generation pre-
ceded DHT induced proliferation. Thus, a normal andro-
gen environment likely promotes a balance between 
antioxidant and pro-oxidant activity [69], but both low 
and high androgen environments are pro-oxidant. There-
fore, in our model we assume that both low and high lev-
els of androgen induce the formation of reactive oxygen 
species.
At low levels, ROS act as important intracellular signal-
ling molecules. A number of transcription factors, 
including NF-κB and AP-1 are redox sensitive, and mod-
est levels of ROS are mitogenic. Davies [76] reported that 
exposure of fibroblasts to 3-15 μM of H2O2 resulted in a 
mitotic response, while levels an order of magnitude 
higher (250-400 μM H2O2) induced permanent growth 
O2
•−
O2
•−
O2
•−
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Page 8 of 28arrest. Very high levels of H2O2 caused either apoptosis 
(500-1000 μM) or necrosis (5-10 mM).
We assume both low and high concentrations of Ct 
induce ROS and that there is some background level of 
ROS independent of androgens. We choose S to repre-
sent ROS and formally take,
Here, μ is the background ROS level, and ROS is induced 
by both low Ct and high Ct according to the first and sec-
ond Hill functions, respectively. The half-maximal Ct for 
ROS induction by low androgen is θ1, and θ2 is the half-
maximal Ct for high androgen induced ROS. We leave the 
Hill coefficients n and m nspecified at this point. We 
leave S a unit-less measure, but for future parametriza-
tion we could let S represent, for example, H2O2 equiva-
lents with units μM.
Broadly, we assume that prostate proliferation is induced 
by increasing concentrations of such complexes, and a 
high cell count inhibits proliferation. Low AR:ligand 
complex concentration induces apoptosis, and there is 
always some small baseline turnover rate (1-2% of cells 
turnover daily in the healthy prostate [22]). We assume 
that modest levels of ROS induce proliferation, while 
higher levels cause growth arrest and apoptosis. These 
assumptions lead to our formal choices for M(Ct, S) and 
N(Ct, S),
The maximum per-capita proliferation rate is r, and the 
maximum death rate is δ + δ0. The specific formal forms 
for M(Ct, S) and N(Ct, S) are chosen as follows. First con-
sider M(Ct, S), the per-capital rate of proliferation. The 
proliferation signal due to direct stimulation by andro-
gens should increase monotonically with Ct, but given the 
biophysical limitations on the rate that cells can grow and 
divide, it must be bounded for large Ct. The commonly 
used Hill function is a reasonable heuristic choice that 
satisfies these criteria. Since androgens have an array of 
mitotic effects we expect some cooperativity in the over-
all response and take the Hill coefficient to be 2, yielding 
a sigmoidal response curve. Any Hill coefficient greater 
than 1 would yield a sigmoidal curve--we use 2 as a first 
approximation. Thus we arrive at the function 
.
The proliferation signal due to ROS must pass through 
the origin, i.e. the response must be 0 when the ROS level 
is 0. It should be large for low S and, since growth arrest 
occurs at high ROS concentrations, it should attenuate as 
S becomes large. Qualitatively, the function ϕSexp(1 - ϕS) 
gives this behavior.
Finally, proliferation is attenuated as a nonlinear rate by 
the presence of other epithelial cells, and we use the term 
-σP to represent this growth inhibition. This second-
order attenuation of growth is equivalent to a logistic 
model, and a possible alternative approach would be to 
attenuate M(Ct, S) according to an explicit logistic term 
with a carrying capacity. This term prevents unbounded 
growth and causes prostate epithelial count to have an 
equilibrium point for any Ct and S.
Now consider N(Ct, S), the per-capital death rate. The 
death rate due to low androgen must increase monotoni-
cally as Ct decreases. Since such death is generally due to 
the orderly process of apoptosis, it will occur at a finite 
maximum rate when Ct = 0. Similar to the mitotic signal, 
the apoptotic signal can therefore be modeled by a Hill 
function: . The death rate due to high 
ROS levels should increase as S increases. While for very 
large S there may not be a well-defined maximum death 
rate as massive cellular insult will result in necrosis, it is 
unlikely that necrosis will occur under the physiologically 
feasible range for S. Therefore, we assume apoptosis 
occurs at a defined maximum rate for large S and again 
choose a Hill function to represent the apoptotic 
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Page 9 of 28response to ROS: Sq/(ωq + Sq). Apoptosis also occurs at 
the background per-capita rate of δ0:
Our incorporation of S as a function of Ct into the equa-
tion for dP/dt allows both the direct and indirect ROS 
mediated effects of androgens on prostate growth to be 
incorporated into a single differential equation. This con-
struction is somewhat similar to the ecological model of 
planktonic algae interaction with vegetation in shallow 
lakes by Scheffer et al. [77].
Prostate Evolution Model
Because of the importance of the AR in prostate cancer 
progression, we investigate how different androgen envi-
ronments select for cell strains expressing different levels 
of the AR, i.e. we examine selection upon Rt. To model 
competition between a large number of cell strains that 
evolve in time, we propose a state-transition model where 
cells transition between states that each represent a dif-
ferent level of Rt expression. To derive the model, we 
make the following assumptions:
1. All epithelial cells express a constant amount of the 
AR (Rt). Cells can mutate to express more or less AR. 
Each mutation changes AR expression by only a small 
amount.
2. There are a finite number of prostate epithelial 
strains, each of which expresses a different level of the 
AR. A strain is defined by the level of AR expression. 
Therefore, mutation causes cells to transition 
between strains (or states).
3. All cells within each strain proliferate and die 
according to the prostate-growth model.
More formally, we define a set of states:
Each state represents a strain of prostate cells that express 
a different total AR concentration (i.e. Rt), and Rt varies 
linearly with i. Cells transition from Pi to Pi-1 and Pi+1 at 
first-order rate γ, representing mutation. The effective 
androgen concentration for strain i, , is determined 
according the chemical kinetics model, as is the ROS 
level, Si. Populations of each strain grow according to the 
prostate-growth model. The growth model is modified so 
that each strain grows independently, but growth is atten-
uated according to the total prostate cell count, ΣPi. For-
mally,
For example, assume that there are 100 states (Q = 100) 
representing epithelial cell strains with Rt ranging from 15 
to 114 nM. The cells in, say, state 50, have Rt = 64 nM. The 
cells in this state mutate out of the state at rate 2γ, repre-
senting even distribution to states 49 and 51. Moreover, 
cells from state 49 and from state 51 each mutate into 
state 50 at rate γ. In state 49, Rt = 63 nM and in state 51, Rt 
= 65 nM. Proliferation and death occurs in each state 
according to the growth model, as represented by the 
 terms.
This approach is designed to predict how quickly the 
average level of AR expression in the prostate will 
increase under different androgen environments, and to 
what level the AR will ultimately be expressed. The aver-
age level of AR expression for the prostate as a whole is 
calculated as a weighted average:
Parametrization
AR Kinetics Parametrization
Since we impose serum T (TS), we need to know the likely 
physiologic range of this variable. In brown Norway rats, 
serum T averaged 5.03 nM and 4.85 nM in young rats and 
3.19 and 2.77 nM in old rats in [78] and [66]. Therefore, 
3-6 nM is the likely normal physiologic range of serum T 
in rats.
We note that there are a number of published values for 
testosterone and DHT serum and prostate concentra-
tions for both humans and rats. In [79], serum T was 4.95 
nM, serum DHT was 1.3 nM, prostate T was 11.8 nM, 
and prostate DHT was 40.6 nM for the rat. Other authors 
have reported intraprostatic DHT concentrations 15-20 
times T concentration [60]. In the rat, prostate T and 
DHT concentrations were 2.15 nM and 61.29 nM in [60] 
and 1.8 nM and 53 nM in [25]. In man, prostate T and 
DHT were 1.5 nM and 18.2 nM in [34]. Prostate testoster-
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Page 10 of 28one concentration can be much higher than serum con-
centration [60,79], suggesting that most is intracellular. 
DHT prostate concentration can be over 50 times that of 
serum concentration, is produced in the intracellular 
compartment of the local tissue, and thus must be nearly 
entirely intracellular.
Values for most of the basic kinetic parameters 
, and KM are available directly 
from empirical biological data; these values with refer-
ences are given in Table 1. The other parameters, λ, U, α, 
βD, have been estimated from a combination of empirical 
data and steady state analysis.
Several groups have measured binding kinetics for test-
osterone and DHT to the AR. Wilson and French [80] 
measured ka = .14 nM-1 hr -1, kd = .069 hr-1, and KD = .49 
nM for testosterone, and ka = .053 nM-1 hr-1, kd = .018 hr-
1, and KD = .34 nM for DHT. In Dunning R-3327 rat pros-
tate carcinoma, the KD of 0.5 nM for DHT was similar to 
normal tissues, but the dissociation half-lives for of 60 hr 
and 160 hr for testosterone and DHT, respectively, were 
much longer [81]. Nevertheless, testosterone always dis-
sociates from the AR 2.5 to 3 times faster than DHT does 
[81].
The AR is unstable in the absence of its ligand. Gregory et 
al. [82] studied several androgen-dependent and recur-
rent cancer lines, and found that greater AR stability in 
the absence of ligand was associated with recurrence. 
Without ligand, the degradation half-life of AR was 3.0 
hrs in androgen dependent LNCaP cells, and was greater 
than 12 hrs for recurrent CWR22 cells, a half-life report-
edly comparable to that in the presence of ligand.
In the absence of any direct estimates, we use the follow-
ing method to estimate the AR concentration within 
prostate cells. Wilson and French [80] reported a super-
natant AR content in the rat prostate of 80-140 fmol/mg 
cytosol protein, and an AR content of 80-150 fmol/mg 
cytosol protein was reported for the rat Dunning R-3327 
androgen-dependent prostate carcinoma [81]. A cDNA 
encoding the AR predicts a MW of 98,918 [83], and there 
are 200-300 g/L of protein in cellular interiors [84]. From 
this, it can be calculated that 1 fmol AR/mg cytosol pro-
tein corresponds to an intracellular concentration of 0.2-
0.3 nM, and intracellular AR concentration is likely 
between 16 and 45 nM. This yields the likely total AR 
concentration, Rt, which equals R + CT:R + CD:R.
The influx of free testosterone into the prostate, U, is 
determined as an empirical function of serum testoster-
one based upon the data of Wright et al. [60], who mea-
sured intraprostatic testosterone and DHT 
k k k k ka
T
d
T
a
D
d
D
R T cat, , , , , ,β β
Table 1: AR Kinetics Parameters. Parameters and baseline values for the AR kinetics model.
Parameter Meaning Value Reference
T:AR rate of association .14 nM -1hr -1 [80]
T:AR dissociation rate .069 hr-1 [80]
DHT:AR rate of association .053 nM-1 hr -1 [80]
DHT:AR dissociation rate .018 hr -1 [80]
βR Free AR degradation rate ln(2)/3 hr -1 [82]
βT Free T degradation rate ln(2)/3 hr -1
βD Free DHT degradation rate ln(2)/9 hr -1 [61], see text
α 5α-reductase concentration 5.0 mg L -1 see text
kcat Rate of T T DHT conversion by 
5α-R
18 ± 15 nmol hr -1 mg -1 [97]
KM Michaelis constant for 5α-R 75 ± 33 nM [97]
KI Michaelis constant for 
finasteride
.46 ± .21 nM [97]
ka
T
kd
T
ka
D
kd
D
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Page 11 of 28concentrations as functions of serum testosterone in cas-
trated rats both with and without treatment with the 5α-
reductase inhibitor finasteride; this data is shown in Fig-
ure 1. We use the data-set where finasteride was present, 
and since almost no DHT was produced we simply take α 
= 0 (in reality, the effective KM has been made very large). 
We also ignore AR production and degradation and 
impose the total AR concentration Rt = 16-45 nM, leaving 
U as the only free parameter. Running the system to 
steady state then allows U to be determined as a function 
of TS and Rt, as shown in Figure 2. A higher Rt implies a 
lower influx U, as when more AR is present, more andro-
gen is bound and thus degrades more slowly. To deter-
mine α (5α-reductase concentration) and βD (DHT 
degradation rate), the data-set of Wright et al. where fin-
asteride was not present is used in conjunction with the 
empirically determined function U. We have found that 
setting Rt = 45 nM and using the corresponding function 
for U gives the best fit to the data. A good algebraic fit to 
the U curve for Rt = 45 nM is
This is also indicated in Figure 1. From this data-set, we 
also estimate that α = 5 mg L-1 and βD = ln(2)/9 hr-1. The 
half-life of DHT in the rat prostate is reportedly greater 
than 6 hours [61]; a degradation rate of βD = ln(2)/9 hr-1 is 
consistent with this. Using these parameters, the pre-
dicted T and DHT concentration versus the actual con-
centration as a function of serum testosterone is shown in 
Figure 3. Predicted T and DHT concentrations for total 
5α-reductase blockade (α = 0) versus actual values for 
finasteride treatment are also shown in Figure 3.
This parametrization shows that when the total AR con-
centration is a constant, a good fit to the data can be 
made, and suggests that AR production is regulated 
according to some homeostatic set point. We have been 
unable to favorably compare our results to the data of 
Wright et al. [60] if AR production, i.e. λ, is a constant. 
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Figure 1 Intraprostatic concentrations of T and DHT when 5α-reductase is and is not blocked (i.e. finasteride treatment) in the rat. Data is 
from Wright et al. [60].
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lated by free AR, or alternatively and more realistically, 
negatively regulated by androgen:AR complexes.
Indeed, AR mRNA and protein levels are clearly regu-
lated by androgens, and this has mainly been studied in 
rat models of castration and androgen reintroduction. It 
has been consistently shown that AR mRNA levels 
increase dramatically following castration [27,85-87] and 
that androgens down-regulate AR mRNA in a receptor-
mediated fashion [85]. However, castration also dramati-
cally reduces AR protein levels [27,63,88]. Doorn et al. 
found that subsequent reintroduction of androgen rap-
idly increases the concentration of nuclear AR bound 
androgen, and the AR protein level rebounds to the pre-
castration level within 2 days [63]. Steinsapir et al. found 
that cytosolic AR was replenished within 3 hours of test-
osterone reintroduction, and proposed that testosterone 
regulates AR levels through its effect upon receptor half-
life [89].
Consistent with these results, Mora et al. [87] showed 
that, in previously castrated rats, administration of test-
osterone increased nuclear AR concentration after 1 hr. 
Testosterone administration for 1 hr did not affect mRNA 
levels, and positive regulation of transcriptional activity 
was ruled out as the underlying mechanism. Further-
more, inhibiting protein synthesis inhibited the increase 
in AR, and Mora et al. concluded that AR protein synthe-
sis was involved in the mechanism for AR protein 
increase following testosterone administration.
Since AR binding to androgen greatly increases its stabil-
ity, androgen administration could increase the level of 
AR protein by increasing its stability. These results are 
collectively consistent with the notion that mRNA pro-
duction and AR protein synthesis are both negatively reg-
ulated by androgens, but that a nonlinear decrease in the 
stability of AR occurs for very low androgen concentra-
tion. We have examined the production rate, λ, and effec-
tive turnover rate of AR, , in our model when the 
total AR concentration is held constant. That is, we solve 
for λ using steady state analysis and use
This gives  at steady state. We have 
found that AR is bound for much of the time for all but 
βTEffective
dRt
dt
RT t= −λ β Effective . (19)
β λT tREffective = /
Figure 2 Influx of free testosterone, U, as function of serum testosterone, as determined using the data of Wright et al. [60] The algebraic fit 
for U(TS) with Rt = 45 nM is also indicated.
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Figure 3 T and DHT concentrations predicted by the AR kinetics model versus the actual concentrations in Wright et al. [60]as a function of 
serum testosterone. Rt is fixed at 45 nM, all other parameters are fixed at the baseline values. (a) 5α-reductase allowed, α = 5 mg L-1. (b) 5α-reductase 
blocked, α = 0 mg L-1.
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turnover rate does indeed increase nonlinearly as serum 
testosterone goes to 0. This result may explain the contra-
dictory results that variously imply positive or negative 
regulation of AR by androgens and the puzzling discon-
nect between increased AR mRNA levels but decreased 
protein levels seen after castration.
While such results imply that the AR level is not constant, 
castration is an extreme scenario (especially in the rat), 
and since AR levels rebound shortly after androgen rein-
troduction [63,89], it is likely that the AR level is actually 
relatively constant except in the case of extreme androgen 
deprivation. Therefore, we assume that there exists some 
homeostatic AR concentration, Rt, that along with CT:R 
and CD:R determines the AR production rate
where  is the normal AR turnover rate.
Growth Model Parametrization
The growth of the prostate epithelium, in our model, is 
governed solely by the intraprostatic weighted AR:ligand 
complex concentration, Ct, and the prostate cell count, 
P(t). There are two independent proliferation signals, one 
mediated by Ct and the other by S, and two similar death 
signals. In addition, the summed proliferation signal is 
attenuated by crowding and there is a background death 
rate. The shapes of these signals are collectively deter-
mined by the parameters θ1, θ2, φ1, φ2, ϕ, ω, n, m, and q. 
We have chosen values for these parameters based upon 
our determination of physiologic (and super- and sub-
physiologic) parameter values for serum T and prostatic 
AR and the resulting Cts; they are reported in Table 2. We 
view these, therefore, as a first approximation.
Oxidative stress, S, is shown as a function of Ct in Figure 
4. Figure 5 shows the proliferation and death signals 
directly due to Ct and S. It also shows the proliferation 
and death signals mediated by S as a function of Ct, since 
S is itself a function of Ct. Such curves emphasize that Ct 
is the ultimate mediator of all proliferation and death 
(besides crowding effects) in our model. These figures 
λ β= − −R t TR DRR C C*( ), (20)
βR*
Table 2: Growth Model Parameters. Parameters and baseline values for the prostate growth model.
Parameter Meaning Value
θ1 Half-maximal Ct for low androgen induced 
ROS
30 nM
θ2 Half-maximal Ct for high androgen 
induced ROS
225 nM
μ Background ROS level .05
n Hill coefficient for low androgen induced 
ROS
4
m Hill coefficient for high androgen induced 
ROS
4
φ1 Half maximal Ct for high androgen induced 
proliferation
110 nM
φ2 Half maximal Ct for low androgen induced 
apoptosis
40 nM
ϕ Determines form of ROS induced 
proliferation signal
4
ω Half-maximal S for ROS induced death 1
q Hill coefficient for ROS induced death 8
σ Mass action coefficient for proliferation 
attenuation
1.5 × 10-10 cell-1 hour-1
δ Background death rate .004 hour-1
r Maximum per capita growth rate ln(2)/24 hour-1
δ Maximum per capita death rate ln(2)/24 hour-1
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Page 15 of 28disregard the -σP crowding term as this varies depending 
upon prostate size. The qualitative form of these curves is 
preserved over most parameter space.
Results and Discussion
Basic Dynamics of the AR Kinetics Model
We briefly characterize the basic dynamics of the AR 
kinetics model. The time-dependent dynamics of the 
model are demonstrated by initially setting Rt to a con-
stant and all other variables to 0. Serum T concentration 
is prescribed, and the model is run to steady state, as 
shown in Figure 6. For baseline parameter values, the free 
T concentration is always small, as most T is rapidly con-
verted to DHT. There is a transient peak in T:AR complex 
concentration early in time, but the DHT:AR complex 
dominates within several days; this pattern is a conse-
quence of the time it takes 5α-reductase to produce DHT. 
For physiologic values of serum T and prostate AR, once 
steady state is reached most androgen is bound its recep-
tor, and nearly all intraprostatic androgen is DHT. These 
dynamics are biologically expected.
At steady state, most AR is bound at physiological levels 
of serum testosterone. For superphysiological serum test-
osterone, intraprostatic free DHT increases while 
AR:ligand complex concentration levels off; intrapros-
tatic free T also increases modestly with high serum T. 
This qualitative pattern is observed regardless of the con-
centration of AR; an example is shown in Figure 7. While 
this qualitative pattern is consistent, the absolute levels of 
bound androgens increase linearly with AR concentration 
regardless of serum testosterone.
Sensitivity of AR Kinetic Parameters
We examine how altering several central parameters in 
the kinetics model influences the steady state AR:ligand 
concentrations under different androgen environments. 
Lea and French [81] found that while the KD for DHT:AR 
binding was the same in carcinomas as in normal tissue, 
the actual on/off rates were much slower. In our model, 
changes in the on/off rates do not affect the steady state 
as long as the KDs remain constant, suggesting slower 
rates offer no benefit to carcinoma growth. However, our 
model does not take into account the effect of increased 
complex life-spans, and it may be useful to consider aver-
age life-span in future work.
We examine the parameters associated with 5α-reduc-
tase: α, kcat, and KM and η (i.e. effective KM). All affect the 
steady state in a similar manner and change the ratio of 
DHT:total androgen in a nonlinear manner. The total 
amount of androgen in the prostate also decreases mod-
estly in a nonlinear fashion when 5α-reductase is inhib-
ited.
Finally, we investigate the degradation rates of R, T, and 
D. We find that for normal physiologic serum T, only βD, 
Figure 4 Oxidative stress, S, as a function of Ct.
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Page 16 of 28the degradation rate of DHT, has any significant effect on 
either total prostate androgen or the ratio of DHT:T; both 
decrease dramatically with increasing βD. At low serum T, 
βR, the degradation rate of free AR, is also important. 
Increasing βR significantly reduces total androgen, but 
does not affect the DHT:T ratio. Modifying the rate at 
which free T degrades, βT, has only minor effects.
Gregory et al. [82] found that increased AR stability in 
the absence of ligand was associated with recurrence of 
androgen-dependent cancer cell lines. Our model sup-
ports the notion that in a low androgen environment, 
increasing the stability of free AR (i.e. reducing βR) will 
augment the response to androgens by increasing the 
concentration of receptor bound androgen. Therefore, 
increasing the half-life of the free AR is one pathway 
through which cancers may overcome androgen block-
ade.
Steady State Cell Count, Turnover
We now examine the model dynamics at the prostate 
growth level. The steady state prostate mass as a function 
of serum testosterone for different levels of Rt is shown in 
Figure 8, and mass as a function of Rt for different serum 
T levels is given in Figure 9. Units have been converted 
from cell count to approximate mass, but due to the ad 
hoc parametrization of the growth model the absolute 
numbers are unimportant - it is the shapes of the curves 
that matter. We emphasize that we are not attempting to 
relate these curves to any specific data, but instead are 
exploring the qualitative behavior that results in a model 
derived from biological principles.
For higher levels of serum testosterone, prostate mass 
peaks at some level of Rt and then declines. This decline 
occurs because the growth signal induced directly by 
androgens saturates for high Rt (or Ct) while ROS levels 
increase. This causes the ROS proliferation signal to 
attenuate, while the death signal increases in magnitude. 
Figure 5 Curves for the different growth signals. Because the ROS level S is a function of Ct, the proliferation and death signals mediated by S can 
be given as a function of either S (as in (a)) or of Ct (as in (b)). Attenuation of proliferation by crowding (the -σP) is disregarded here because it affects 
the proliferation signal in a way that depends on the instantaneous prostate mass. (a) Prostate cell growth and death signals due to ROS as a function 
of S. (b) Prostate cell growth and death signals due to ROS given as a function of Ct, as S is itself a function of Ct. (c) Proliferation and death signal due 
to the effective AR:ligand concentration, Ct. (d) Overall proliferation and death signals mediated by both ROS and AR:ligand concentration. Because 
ROS level is a function of the AR:ligand concentration, Ct, the overall signal can be given as a function of only Ct.
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Figure 6 Time-series for the AR kinetics model. Free AR is set to 45 nM as an initial condition; all other variables are initially zero and baseline pa-
rameter values are used. Serum T is prescribed at 5 nM, inducing an influx of testosterone, and the model runs to a steady state. (a) Time-series for all 
model variables - free T, free DHT, T:AR complex, DHT:AR complex, and free AR. (b) Time-series for total T, DHT, and AR concentrations. (a) Time-series 
for all model variables - free T, free DHT, T:AR complex, DHT:AR complex, and free AR. (b) Time-series for total T, DHT, and AR concentrations.
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or death, the internal cell turnover rate varies with Rt and 
TS. This will affect the rate at which evolution can occur, 
as greater cell turnover will presumably increase the rate 
at which mutations accumulate. Lower androgen always 
increases the turnover rate in this model. Figure 10 shows 
turnover as a function of serum T for several levels of 5α-
reductase inhibition.
We have performed a sensitivity analysis of all the growth 
model parameters and found that the qualitative shapes 
of the mass and turnover curves are preserved.
Evolution and Selection for Elevated AR Expression
We use the state-transition model for the evolution of AR 
expression to determine how different androgen environ-
ments influence the prostate-wide evolution of AR 
expression. We choose our model to have 100 states rep-
resenting Rt from 15 to 114 nM. That is, we set Q = 100 
and , the total AR level at state i, to be 14 + i nM, i 8 
{1,2,...,100}. The total number of cells in each state is 
tracked through time, and the average Rt at all time steps 
is calculated. Figure 11 shows the evolution of average Rt 
under different serum T levels. 5α-reductase inhibition, 
e.g., through finasteride treatment, also induces a low 
androgen environment, and Figure 12 shows how evolu-
tion changes under increasing values of η (increasing 
effective KM).
In general, our results indicate that physiologic serum T 
selects for modestly increased AR expression, as do all 
androgen environments. Therefore, the model predicts 
that even in healthy men, prostate epithelial cells will 
increase their AR expression and hence potential for 
malignancy with time. Under high serum T, selection for 
an elevated Rt is actually slighter weaker. In comparison, 
low androgen environments (i.e. low serum T or low 5α-
reductase) demonstrate the greatest selection for 
increased AR expression. Generally, the widespread 
appearance of strains expressing high levels of AR occurs 
abruptly and later in time than under normal androgen 
levels. While this selection occurs later in time, a higher 
average Rt is ultimately obtained.
We have performed a sensitivity analysis to determine 
whether this behavior is preserved under different 
growth model parameter values. We have found that the 
prediction that low androgen selects for a greater final Rt 
Rti
Figure 7 Concentrations of free T, free DHT, T:AR complex, and DHT:AR complex at steady state as a function of serum testosterone. Rt is 
fixed at 45 nM.
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govern the level of ROS, have the greatest effect on the 
dynamics. Increasing μ, the background ROS level, 
causes low androgen to select for higher Rt earlier in time. 
Decreasing θ2, which implies higher ROS for relatively 
lower levels of Ct, also decreases the time to selection for 
Rt. Increasing θ1, which implies ROS is elevated under a 
lesser degree of androgen insufficiency, changes the 
dynamics most significantly. Large values of θ1 result in a 
two-phase pattern of selection for high Rt in low andro-
gen environments: AR initially increases slowly, there is a 
sudden jump, and finally increases slowly again. This and 
a more typical pattern of AR evolution for low versus 
high androgen environments are shown in Figure 13. 
Overall, low androgen appears to select for a greater final 
Rt in all parameter space, and this selection becomes 
apparent later in time than under normal androgen for 
most parameter space.
These results suggest that a low androgen environment 
may delay the development of a malignant phenotype, 
but result in a more malignant or therapy-resistant strain 
later in time. This result could also be interpreted to 
mean that low androgen reduces the overall incidence of 
cancer, as the expected time to the development of a 
malignant strain is increased, but those cancers that do 
arise may be more aggressive. This notion is consistent 
with the results of finasteride treatment in men [50].
Conclusions
We have developed a preliminary model of the binding 
kinetics of prostate androgens, their relationship to pro-
liferation and death in the prostate epithelium, and the 
evolution of AR expression, and hence malignant poten-
tial, in different androgen environments. Thus, we have 
modeled prostate carcinogenesis at three distinct scales. 
At the receptor kinetics scale, we have described the 
essential interactions between T, DHT, and AR, and have 
fully parameterized this model using biological data. At 
the prostate organ level, we have taken both the direct 
and indirect ROS mediated effects of androgens on epi-
thelial proliferation and apoptosis into account. At the 
highest scale, we have employed a state-transition model 
to study selection between epithelial strains expressing 
different levels of AR, and whose behavior is determined 
by the coupled AR kinetics and prostate growth model. 
Results using this evolutionary modeling framework have 
suggested that a low androgen environment caused either 
by low serum testosterone or clinical intervention with 
5α-reductase inhibitors can increase selection for AR 
overexpression in prostate epithelium, while high andro-
gens may weakly protect against AR overexpression. As a 
Figure 8 Steady state prostate mass as a function of serum testosterone for different levels of Rt. Note that below Rt = 25 nM mass quickly 
decreases for all serum T, while there is a reasonable stable region between 25 and 45 nM, after which mass increases roughly linearly with Rt before 
leveling off. For higher values of Rt than those displayed, increases in serum T can cause a reduction in prostate mass (see Figure 9).
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suggest the following hypothesis: that low intraprostatic 
AR:ligand concentrations, caused either by low serum 
testosterone or 5-α reductase inhibition, drive evolution 
towards decreased dependence upon androgens in pros-
tate epithelium, therefore increasing the risk of cancer 
that is resistant to hormonal therapy. Moreover, such 
cancers may arise later in life than those cancers with 
lower sensitivity to androgens.
We must emphasize the preliminary nature of the model, 
and there are likely many ways to model the phenomenon 
that we are studying. We have used only one approach, 
and there is much room for improvement as well as 
future work. In particular, we have not (explicitly) mod-
eled the essential interactions between stromal and epi-
thelial cells that mediate prostate growth. Moreover, we 
have ignored the heterogenous architecture of the pros-
tate. Not only do different prostate lobes display different 
responses to androgens [66,67], but prostate epithelial 
cells are exposed to different levels of androgen and are 
differentially sensitive to such hormones.
We have not explicitly modeled the role of the prostate 
vasculature. Delivery of testosterone from the serum to 
the prostate is dependent upon prostate size and the state 
of the vasculature, both of which are themselves regu-
lated by prostatic androgen, and vascular regression pre-
cedes prostate involution in castration models [22,72]. 
We have taken this into account to some degree through 
the use of an empirical function to describe testosterone 
flux into the prostate as a function of serum testosterone, 
as prostate weight is also a function of serum testoster-
one. However, we have assumed homogenous delivery to 
all cells, and considering the spatial dynamics of test-
osterone delivery is an important potential modification 
to the model. Moreover, vascular regression causes 
hypoxia and induces oxidative stress, which we have also 
partially taken into account by making S increase with 
low androgen, but hypoxia is also likely spatially hetero-
geneous.
While much mechanistic and spatial complexity has been 
ignored, the relative simplicity of our model of tissue-
level prostate growth is also a strength in that it allows 
several of the competing effects of androgens on prostate 
epithelium--i.e., oxidative stress, proliferation, apoptosis-
-to be subsumed into a single differential equation. Thus, 
the model includes the essential effects of androgens with 
minimum complexity, and the qualitative effects of 
androgens on the prostate epithelium can be explored in 
a minimal formal setting. However, we have not rigor-
ously parametrized this level of the model, although its 
qualitative behavior is preserved over a wide range of 
parameter values. It follows that a weakness of the model 
Figure 9 Steady state prostate mass as a function of Rt for different serum testosterone concentrations. Note that for sufficiently high AR con-
centrations, increases in serum T actually reduce prostate mass.
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fronting the model with quantitative data other than in 
regards to its qualitative predictions.
Our parametrization and investigation of the AR kinetics 
model has yielded some insight into AR dynamics. Our 
parametrization suggests that AR levels are constant 
under the physiologic range of serum androgens. We 
have found that increased stability of free AR has little 
effect on AR dynamics under normal androgen levels, but 
in a state of androgen deprivation, increased stability of 
the free receptor significantly increases intraprostatic 
AR:ligand concentrations, implying a role for such a 
modification in HR cancer, as seen in [82]. Moreover, 
decreasing 5α-reductase activity (through either α, kcat, 
or KM), can decrease AR:ligand concentrations in a non-
linear manner.
In our model, when serum T is low or 5α-reductase is 
inhibited, the prostate epithelial cell mass is much lower. 
Thus, there is simply less substrate for selection to act 
upon when serum T is low. However, in such an environ-
ment the cell turnover rate is higher. Therefore, muta-
tions may arise more rapidly and be selected for more 
quickly in a low androgen environment despite the lower 
cell count.
This, along with the results from our state-transition 
model, support the notion that low androgen levels can 
induce selection for phenotypes with increased AR 
expression. Such a phenotype may be considered to have 
a higher potential for malignancy or be "pre-malignant." 
In particular, such a phenotype is likely to be resistant to 
androgen ablation therapy, and a great deal of experimen-
tal and clinical literature supports the notion that low 
androgen levels induce treatment resistant cancers. Sev-
eral studies by Labrie et al. [90,91] on mouse mammary 
carcinoma cells cultured in different concentrations of 
DHT demonstrated that a single tumor line can yield 
wide phenotypic variety in sensitivity to DHT (KM for 
growth varied up to 1,250-fold in [90]) and that low DHT 
concentration selected for clones that were hypersensi-
tive to androgen, requiring minuscule DHT levels for 
growth. Such hypersensitive clones would likely demon-
strate little if any response to androgen blockade.
A number of clinical studies have shown that low test-
osterone levels predict a poor response to androgen dep-
rivation. In 1981, Adlercreutz et al. [43] found that men 
with lower serum testosterone had a poorer response to 
androgen deprivation. A number studies over the follow-
ing decade consistently found low serum testosterone to 
be associated with poor responses and shorter survival 
Figure 11 Evolution of average Rt in the state-transition model under different serum T. AR expression is presumably a marker for the malig-
nant potential of a strain. Low serum T selects for higher Rt than the normal environment (serum T = 5 nM), but takes longer to do so. High serum T 
selects for a slightly lower Rt.
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Page 22 of 28[40,42,44,45,48]. In one study of metastatic cancer, pre-
treatment serum T was a stronger predictor of treatment 
response than the extent of bone metastases [46,47]. Fur-
thermore, in some cases high serum T predicted a better 
response to therapy [43,48].
Daniell [49] reported men with testicular atrophy pre-
sented with highly undifferentiated tumors and had a 
much worse prognosis following orchiectomy than those 
without atrophy. In a study of Japanese men, those with 
metastatic cancer had higher serum T levels than those 
with non-metastatic cancer, but high T predicted a good 
response to hormonal therapy [92]. Several studies have 
also found that in clinically localized prostate cancer a 
low pretreatment serum T is associated with a more 
advanced pathological stage and increases the probability 
of non-organ confined disease [93-95].
Many studies also suggest that low serum testosterone 
not only predicts a poor response to hormonal therapy, 
but also increases the risk of prostate cancer. Men with 
low free and total testosterone levels had a significantly 
higher rate of cancer than those with high serum testose-
rone [36]. Schatzl et al. found that not only did men with 
low testosterone have more aggressive cancers, but AR 
expression was also elevated in these patients [37].
On the other hand, several authors have concluded that 
low serum testosterone predicting more advanced dis-
ease or poorer response to therapy simply reflects the 
poorer health of such patients rather than indicating any 
causal role for testosterone in cancer development 
[40,41]. However, on sum the clinical evidence and our 
theoretical results suggest that low serum testosterone 
induces selection for AR overexpression, which in turn 
may predispose cancer to treatment-resistance.
Following the results of the PCPT, which showed an over-
all reduction in cancer incidence for those taking finas-
teride but an increase in high-grade tumors [50], great 
controversy has surrounded the possible role of the drug 
in cancer etiology [52]. It is not clear why inhibiting DHT 
would be protective against cancer if it is true that low 
serum T can promote cancer. It seems unlikely that inhib-
iting DHT within the prostate would have a qualitatively 
different effect on androgen-mediated cell activities than 
lowering serum T, and one recent study found that low 
intraprostatic DHT increased cancer aggressiveness [96].
In our model, the effect of 5-α reductase inhibition on 
selection for AR overexpression is similar to the effect of 
low serum T. That is, AR overexpression is selected for 
more strongly, but the expected time to such overexpres-
sion being observed is greater than in a normal androgen 
environment. Therefore, we expect 5-α reductase inhibi-
tion to similarly increase risk for therapy-resistant and/or 
aggressive prostate cancer. Indeed, as early as 1993, Mar-
tel et al. [79] expressed concern that the use of 5α-reduc-
Figure 12 Evolution of average Rt in the state-transition model under different levels of 5α-reductase inhibition by finasteride.
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Figure 13 Evolution of average Rt in the state transition model under high and low serum testosterone concentrations for 2 different val-
ues of the θ1 parameter. For θ1 = 20, the more typical pattern is observed with the appearance of AR overexpression occurring later in time but to 
a greater magnitude under the low androgen environment. A more unique pattern is seen for θ1 = 60. (a) Evolution of average Rt for θ1 = 20. (b) Evo-
lution of average Rt for θ1 = 60.
Eikenberry et al. Biology Direct 2010, 5:24
http://www.biology-direct.com/content/5/1/24
Page 24 of 28tase inhibitors in the treatment of BPH could induce 
selection for therapy resistant cancer cells.
Perhaps low serum T consistently predicts both increased 
cancer incidence and aggressiveness because in men with 
lifelong low testosterone the temporal window where a 
normal or high androgen environment results in greater 
AR expression (see Figures 11 and 12) is usually passed by 
the time cancer is diagnosed in the latter decades of life. 
Finasteride treatment may shift patients to the pattern of 
AR evolution we have observed in low androgen environ-
ments, where the prostate-wide average Rt remains low 
for a long time, but increases dramatically late in time. 
Therefore, in a relatively short temporal window overall 
cancer incidence may be reduced, but a minority of 
patients will cross the threshold for increased AR expres-
sion and experience a high-grade tumor. In light of the 
clinical data on low testosterone and cancer risk, and our 
own results suggesting that the temporal scale for the 
incidence of aggressive cancer under 5α-reductase inhi-
bition is not the same as that for overall cancer incidence 
under normal androgen environments, long-term follow-
up of patients being treated with finasteride is warranted, 
and the response to hormonal therapy among patients 
who do experience prostate cancer should be studied.
In conclusion, our theoretical study suggests that AR 
expression in the prostate increases uniformly with age. 
However, low intraprostatic androgen, whether induced 
by low serum T or 5α-reductase inhibition, can increase 
selection for AR overexpression, and hence increased 
cancer aggressiveness and treatment resistance. This 
overexpression may not manifest itself until relatively late 
in life, so while those with low intraprostatic androgen 
may be at an increased lifetime risk for aggressive cancer, 
they may experience decreased overall cancer incidence. 
This may help to explain the decreased overall cancer 
incidence, but increased risk of high-grade cancer, that 
has been seen in men taking finasteride [50,54].
Reviewers' Comments
Reviewer's report 1
Dr. Ariosto S. Silva (nominated by Dr. Marek Kimmel)
1. The idea proposed in this article that there are "sweet 
spots" in the concentrations of hormones and in stages of 
development of the tumor that guide tumorigenesis and 
lead to therapy resistance is an important concept 
towards personalize cancer treatment. It reminds me of 
the analogy of the pepper shaker and the steak: a little 
pepper makes the steak taste better but a lot of pepper 
makes the steak a lot worse.
I would suggest rewriting this sentence for sake of clarity 
"Most cancers are more aggressive following HR recur-
rence, there are no effective treatments for such cancers, 
and average survival following progression does not 
exceed 15 months [24]." I understood that most cancers 
that recur and are hormone refractory are more aggres-
sive than before treatment and that they do not respond 
to treatment, is this it?
Authors' response: Yes, that is exactly what was meant by 
this sentence. (We would assume that, by definition, any 
cancer that recurs in the face of androgen ablation therapy 
should be considered "hormone refractory.")
2. Please review these two sentences; they seem to mean 
the same thing: "AR amplification occurs in perhaps 30% 
of recurring HR tumors [22]. However, such genetic alter-
ations do not occur in most HR cancers."
Authors' response: Here we are pointing out that while AR 
gene amplification does occur and is not an insignificant 
contributor to HR tumor recurrence, such a genetic alter-
ation does not occur in the majority of HR tumors. You are 
correct that the second sentence is somewhat redundant, 
but we have left it in to emphasize that this is not the dom-
inant pathway by which HR recurrence occurs (although 
we did replace the wording "most HR cancers" by "the 
majority of HR cancers").
3. Please clarify how this paragraph relate to previous 
observation, it seems contradictory that the upregulation 
of AR expression is HR tumors but is also the most 
important pathway: "Upregulation of the AR protein is 
perhaps the single most important pathway by which 
cancers achieve androgen independence. Chen et al. [30] 
found that in 7 prostate cancer xenograft models, 
increased androgen receptor expression was the only 
change consistently associated with HR cancer progres-
sion."
Authors' response: In the previous paragraph, we are 
pointing out that amplification of the AR gene occurs in a 
minority of HR tumors. Increased levels of the AR protein 
itself, whether achieved through gene amplification or by 
other pathways, seems to be the most important (or at 
least most common) pathway to HR tumor recurrence in 
the majority of tumors.
4. Could you please give more details on this trial? The 
subjects had any signal of prostate tumor or the idea is 
that every man would submit to this treatment after a 
certain age? "In the Prostate Cancer Prevention Trial 
(PCPT), finasteride use reduced overall prostate cancer 
incidence, but increased the risk of high-grade cancer 
over 7 years [50]."
Authors' response: The PCPT was a double-blind RCT 
that assigned men with no history of prostate cancer to 
receive finasteride (5 mg) or a placebo daily for 7 years. 
Biopsy was performed on the basis of serum PSA or abnor-
mal digital rectal exam. At the end of the 7-year study 
period, all men who consented received a biopsy. Finas-
teride use reduced overall prostate cancer incidence by 
24%, but increased the risk of high-grade cancer: 37% of 
cancers were high-grade in the treatment group versus 
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in the text.
5. Could you please explain the relationship between a 
smaller prostate and the probability that a biopsy would 
detect cancer? We could imagine that smaller prostates 
would pass the rectal touch exam and thus not be biop-
sied? "Finastide significantly reduced the prostate size in 
those treated, and reduced prostate size can increase the 
probability of cancer detection in biopsy samples, so a 
detection bias could explain the increased rate of high-
grade cancer."
Authors' response: What is being discussed here is not the 
relationship between the prostate size and the probability 
of biopsy based on DRE findings (although you are cer-
tainly correct that a smaller prostate would decrease the 
chance of a positive rectal exam and thus a for-cause 
biopsy).
Rather, it has been argued that given a biopsy occurs, the 
probability that tumor tissue is present in the biopsied tis-
sue sample will depend on the absolute size of the prostate. 
If more normal epithelium is present, as in the case of pla-
cebo-treated men, the probability that tumor tissue is 
detected decreases. Since finasteride treatment reduces the 
prostate volume, a tumor of equal size is more likely to be 
detected in biopsy samples from a finasteride-treated man 
than a placebo-treated man. This has been (hopefully) 
clarified in the text.
6. Please elaborate on how hypoxia may induce increase 
in ROS. One of the explanations for limited effect of radi-
ation therapy in hypoxic areas of tumors in the low levels 
of reactive oxygen species, supposedly due to the lack of 
oxygen. "Hypoxia impairs aerobic respiration, and mito-
chondrial ROS is required for stabilization of HIF-1α 
[97]. Thus, in addition to direct effects on redox related 
enzymes, a low androgen environment also increases 
ROS levels by inducing a hypoxic environment."
Authors' response: Radiation exerts its biological effects 
primarily through the ionization of water:
These and other subsequently generated radical species 
can react with O2 to form reactive oxygen species such as 
the superoxide anion and hydrogen peroxide. These spe-
cies initiate further radical reactions that damage the 
DNA. Therefore, the presence of molecular oxygen in 
tumor tissue, but not necessarily the presence of pre-exist-
ing ROS, is an important determinant of the efficacy of 
radiation therapy.
In a hypoxic environment the electron transport chain is 
impaired and oxygen is less likely to be fully reduced, 
resulting in partial oxygen reduction and ROS generation. 
Such mitochondria generated ROS stabilizes HIF-1α and 
thus activates the cellular response to hypoxia. We have 
modified this section slightly for clarity.
7. The sentence "that low intraprostatic AR:ligand con-
centrations, caused either by low serum testosterone or 
5-α reductase inhibition, drive evolution towards ele-
vated sensitivity to androgens in prostate epithelium, 
therefore increasing the risk of cancer that is resistant to 
hormonal therapy" might be better understood if the 
words "elevated sensitivity" were replaced by "smaller 
dependency."
Authors' response: We have replaced "elevated sensitivity 
to" by "decreased dependence upon."
0.1 Reviewer's report 2
Dr. Marek Kimmel
In the transcription factor literature, there is a significant 
number of papers concerning spatial organization of AR 
activity within the nucleus, leading to effects such as 
hyperspeckling (see the attached paper by van Royen et 
al. 2007 from Houtsmuller's laboratory [98]). Are there 
cancer-specific modifications of such organization which 
might have anything to do with altered expression of AR-
dependent genes?
Authors' response: In this paper, van Royen et al. present a 
model for AR/DNA/cofacter interaction that is modulated 
by binding between the N terminal and C terminal 
domains (N/C interactions) of the AR. Such binding 
appears to prevent cofactor recruitment, and occurs upon 
hormone ligand binding. Following ligand binding, the AR 
translocates to the nucleus, where it is highly mobile. 
Transient binding to the DNA terminates N/C interac-
tions. This allows the C-terminal ligand binding domain 
(LBD) to interact with cofactors containing the FxxLF 
motif, leading to altered transcriptional activity.
It is likely that cancer-specific alterations of the AR that 
affect the spatial kinetics of DNA binding and cofactor 
recruitment play a role in prostate cancer progression and 
its response to treatment. For example, changes in N/C 
interaction might alter co-factor recruitment within the 
nucleus, and altered co-factor activity may be associated 
with HR recurrence. Farla et al. [99]showed that while 
both AR agonists and antagonists cause translocation of 
the AR:ligand complex to the nucleus, only agonists 
caused DNA binding. Mutations in the AR can cause 
antagonists to act as agonists, and these may act by alter-
ing N/C interaction and cofactor recruitment following 
binding. Farla et al. established that DNA binding kinetics 
for mutant ARs bound to anti-androgens were similar to 
the DNA binding kinetics for wild-type ARs bound to ago-
nists. Therefore, modification of DNA binding in the spa-
tial compartment in response to non-canonical ligands is 
likely one pathway by which prostate cancers become hor-
mone refractory. van Royen et al. also found that speckling 
overlaps with, but is not perfectly correlated with, tran-
H O H O e2 2→ +
•+ −
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without DNA binding, so the dynamics of speckling are 
likely a direct result of DNA binding kinetics and subse-
quent interactions with co-factors, etc.
In any case, we would argue that any alteration in the AR 
that affects the transcriptional response to AR:ligand 
binding must necessarily affect the spatial dynamics of AR 
activity in the nucleus. At the phenomenological level, the 
exact molecular mechanisms by which AR activity is 
changed are not as important as how the androgen envi-
ronment selects for altered AR activity in general.
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